Comparison of the peripheral blood eosinophil count using near-patient testing and standard automated laboratory measurement in healthy, asthmatic and COPD subjects

Kirsty Hambleton, Clare M Connolly, Catherine Borg, Joanne H Davies, Helen P Jeffers, Richard Ek Russell, Mona Bafadhel, Kirsty Hambleton, Clare M Connolly, Catherine Borg, Joanne H Davies, Helen P Jeffers, Richard Ek Russell, Mona Bafadhel

Abstract

Near-patient testing (NPT) allows clinical decisions to be made in a rapid and convenient manner and is often cost effective. In COPD the peripheral blood eosinophil count has been demonstrated to have utility in providing prognostic information and predicting response to treatment during an acute exacerbation. For this potential to be achieved having a reliable NPT of blood eosinophil count would be extremely useful. Therefore, we investigated the use of the HemoCue® WBC Diff System and evaluated its sensitivity and specificity in healthy, asthmatic and COPD subjects. This method requires a simple skin prick of blood and was compared to standard venepuncture laboratory analysis. The HemoCue® WBC Diff System measured the peripheral blood eosinophil count in healthy, asthma and COPD subjects with very close correlation to the eosinophil count as measured by standard venepuncture. The correlations were unaffected by disease status. This method for the measurement of the peripheral blood eosinophil count has the potential to provide rapid near-patient results and thus influence the speed of management decisions in the treatment of airway diseases.

Keywords: asthma; chronic obstructive pulmonary disease; eosinophils; near-patient testing.

Conflict of interest statement

Disclosure MB and REKR have received honoraria from AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis and Pfizer, and report no other conflicts of interest in this work. KH, CMC, CB, JHD, and HPJ report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
(A–D) Correlation and agreement plots for total leukocyte, neutrophil and eosinophil cell counts (×109 cells/L) between NPT (HemoCue® WBC Diff System; HemoCue AB, Ängelholm, Sweden) and automated laboratory analyser (Abbott Architect ci8200; Abbott Laboratories, Abbott Park, IL, USA). ● Healthy volunteer controls; □ COPD; Δ asthma. (E–H) Bland–Altman plots for total leukocyte, neutrophil and eosinophil cell counts (×109 cells/L), difference and average between NPT (HemoCue® WBC Diff System) and automated laboratory analyzer (Abbott Architect ci8200). Horizontal lines set at bias and upper and lower 95% CI of the bias. ● Healthy volunteer controls; □ COPD; Δ asthma. Abbreviations: CI, confidence interval; NPT, near-patient testing.
Figure 1
Figure 1
(A–D) Correlation and agreement plots for total leukocyte, neutrophil and eosinophil cell counts (×109 cells/L) between NPT (HemoCue® WBC Diff System; HemoCue AB, Ängelholm, Sweden) and automated laboratory analyser (Abbott Architect ci8200; Abbott Laboratories, Abbott Park, IL, USA). ● Healthy volunteer controls; □ COPD; Δ asthma. (E–H) Bland–Altman plots for total leukocyte, neutrophil and eosinophil cell counts (×109 cells/L), difference and average between NPT (HemoCue® WBC Diff System) and automated laboratory analyzer (Abbott Architect ci8200). Horizontal lines set at bias and upper and lower 95% CI of the bias. ● Healthy volunteer controls; □ COPD; Δ asthma. Abbreviations: CI, confidence interval; NPT, near-patient testing.

References

    1. Crook MA. Near patient testing and pathology in the new millennium. J Clin Pathol. 2000;53(1):27–30.
    1. Fitzmaurice DA, Hobbs F, Murray ET, Holder RL, Allan TF, Rose PE. Oral anticoagulation management in primary care with the use of computerized decision support and near-patient testing: A randomized, controlled trial. Arch Intern Med. 2000;160(15):2343–2348.
    1. National Institute of Clinical Excellence Chronic kidney disease in adults: assessment and management. 2014. [Accessed August 17, 2017]. Available from: .
    1. National Insitute of Clinical Excellence Type 2 diabetes in adults: management. 2015. [Accessed August 17, 2017]. Available from: .
    1. Jensen LA, Onyskiw JE, Prasad NGN. Meta-analysis of arterial oxygen saturation monitoring by pulse oximetry in adults. Heart Lung. 1998;27(6):387–408.
    1. Izbicki G, Abboud S, Jordan P, Perruchoud AP, Bolliger CT. A comparison of a new transtelephonic portable spirometer with a laboratory spirometer. EurRespir. 1999;14(1):209–213.
    1. Burge CB, Moore VC, Pantin CF, Robertson AS, Burge PS. Diagnosis of occupational asthma from time point differences in serial PEF measurements. Thorax. 2009;64:1032–1036.
    1. Birring SS, Heartin E, Williams TJ, Brightling CE, Pavord ID. Peak expiratory flow sequence in acute exacerbations of asthma. BMJ. 2001;322(7297):1281.
    1. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178(3):218–224.
    1. Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47(2):410–419.
    1. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360(9347):1715–1721.
    1. Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2012;186(1):48–55.
    1. Bafadhel M, Davies L, Calverley PM, Aaron SD, Brightling CE, Pavord ID. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur Respir J. 2014;44(3):789–791.
    1. Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Resp Med. 2016;4(5):390–398.
    1. Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J. 2007;29(5):906–913.
    1. Barnes PJ, Dweik RA, Gelb AF, et al. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest. 2010;138(3):682–692.
    1. Osei-Bimpong A, Jury C, McLean R, Lewis SM. Point-of-care method for total white cell count: an evaluation of the HemoCue WBC device. In J Lab Hematol. 2009;31(6):657–664.
    1. Heffler E, Terranova G, Chessari C, et al. Point-of-care blood eosinophil count in a severe asthma clinic setting. Ann Allergy Asthma Immunol. 2017;119(1):16–20.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera